TY - JOUR
T1 - Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms
T2 - An international multicentre study
AU - REQUITE consortium
AU - Aguado-Barrera, Miguel E.
AU - Lopez-Pleguezuelos, Carlos
AU - Gómez-Caamaño, Antonio
AU - Calvo-Crespo, Patricia
AU - Taboada-Valladares, Begoña
AU - Azria, David
AU - Boisselier, Pierre
AU - Briers, Erik
AU - Chan, Clara
AU - Chang-Claude, Jenny
AU - Coedo-Costa, Carla
AU - Crujeiras-González, Ana
AU - Cuaron, John J.
AU - Defraene, Gilles
AU - Elliott, Rebecca M.
AU - Faivre-Finn, Corinne
AU - Franceschini, Marzia
AU - Fuentes-Rios, Olivia
AU - Galego-Carro, Javier
AU - Gutiérrez-Enríquez, Sara
AU - Heumann, Philipp
AU - Higginson, Daniel S.
AU - Johnson, Kerstie
AU - Lambrecht, Maarten
AU - Lang, Philippe
AU - Lievens, Yolande
AU - Mollà, Meritxell
AU - Ramos, Mónica
AU - Rancati, Tiziana
AU - Rattay, Tim
AU - Rimner, Andreas
AU - Rosenstein, Barry S.
AU - Sangalli, Claudia
AU - Seibold, Petra
AU - Sperk, Elena
AU - Stobart, Hilary
AU - Symonds, Paul
AU - Talbot, Christopher J.
AU - Vandecasteele, Katrien
AU - Veldeman, Liv
AU - Ward, Tim
AU - Webb, Adam
AU - Woolf, David
AU - de Ruysscher, Dirk
AU - West, Catharine M.L.
AU - Vega, Ana
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2025/1
Y1 - 2025/1
N2 - Background and purpose: We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies. Materials and methods: Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses. Results: We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91). Conclusions: Our findings indicate strong alignment between healthcare professionals’ and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.
AB - Background and purpose: We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies. Materials and methods: Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses. Results: We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91). Conclusions: Our findings indicate strong alignment between healthcare professionals’ and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.
KW - Correlation measures
KW - Fatigue
KW - Lung cancer
KW - Patient reported outcome measures
KW - Quality of life
KW - Radiation effects
KW - Symptom assessment
UR - http://www.scopus.com/inward/record.url?scp=85213261343&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2024.108072
DO - 10.1016/j.lungcan.2024.108072
M3 - Article
AN - SCOPUS:85213261343
SN - 0169-5002
VL - 199
JO - Lung Cancer
JF - Lung Cancer
M1 - 108072
ER -